Abstract: A display device of the present disclosure includes: a display panel; a frame which is positioned in a rearward direction of the display panel, and to which the display panel is coupled; a substrate which is positioned between the display panel and the frame, and fixed to the frame; a plurality of light sources mounted on the substrate to form a row and a column; a reflective sheet which is positioned on the substrate, and has a plurality of holes through which each of the plurality of light sources passes; and a light pattern which is formed on the reflective sheet, and converts a color of a light provided by the plurality of light sources, wherein the reflective sheet includes: a first hole positioned adjacent to an edge of the reflective sheet; a second hole which is positioned adjacent to the first hole and positioned farther than the first hole from the edge of the reflective sheet; a first area positioned around the first hole; and a second area positioned around the second hole, wherein the light patte

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

Abstract: The present invention relates to a method of treating neuropathy by administering DNA constructs, encoding a human IGF-1 isoform and a human HGF isoform. Further provided herein are various DNA constructs and pharmaceutical compositions including the DNA constructs that can be used for the combination therapy. The present invention provides a safe and effective way of treating neuropathic patients.

Abstract: An etching gas composition includes at least two C3 or C4 organic fluorine compounds and molybdenum fluoride, and the at least two C3 or C4 organic fluorine compounds are isomers.

Abstract: Provided is a substrate processing apparatus including a chamber having a processing space therein, a supporting unit arranged in the processing space, having a substrate located thereon, and including a label material layer including a label material therein, a plasma source configured to generate plasma from a processing gas in the processing space, and a measurement apparatus configured to detect the label material, wherein, when the supporting unit is etched to a depth that is greater than or equal to a first depth, the label material layer is exposed.

Abstract: An etching gas composition includes at least two types of organofluorine compounds of carbon number C3 or carbon number C4, wherein the at least two types of organofluorine compounds are isomeric to each other.

Abstract: An organic light emitting diode includes an anode, an emission layer disposed on the anode and including a host, a phosphorescent dopant represented by Chemical Formula 1 and a fluorescent dopant represented by Chemical Formula 2, and a cathode disposed on the emission layer. In the organic light emitting diode according to an exemplary aspect of the present disclosure, the emission layer is formed by mixing the fluorescent dopant with the phosphorescent dopant including a substituent as an acceptor at a specific site, thereby energy loss during an emission process can be minimized and energy transfer efficiency can be improved and an organic light emitting diode with improved luminous efficiency and an organic light emitting display device having the same can be provided.

Abstract: The present invention relates to a DNA construct encoding one or more human IGF-1 isoforms that can be used for treatment of neuropathy. Further provided herein are a pharmaceutical composition including the DNA construct as an active ingredient and a method of administering the DNA construct for treatment of neuropathy. The present invention provides a safe and effective way of treating neuropathic patients.

Abstract: The present invention relates to methods of treating chemotherapy-induced peripheral neuropathy. In particular, the methods provide a new way of reducing neuropathic pain associated with chemotherapy-induced peripheral neuropathy by administering a nucleic acid construct encoding human HGF proteins. This application further provides nucleic acid constructs, pharmacological compositions, and methods of administration of the nucleic acid constructs that are effective in treating the neuropathic pain.

Abstract: The present invention relates to a DNA construct encoding one or more human IGF-1 isoforms that can be used for treatment of neuropathy. Further provided herein are a pharmaceutical composition including the DNA construct as an active ingredient and a method of administering the DNA construct for treatment of neuropathy. The present invention provides a safe and effective way of treating neuropathic patients.

Abstract: The present invention relates to methods of treating chemotherapy-induced peripheral neuropathy. In particular, the methods provide a new way of reducing neuropathic pain associated with chemotherapy-induced peripheral neuropathy by administering a nucleic acid construct encoding human HGF proteins. This application further provides nucleic acid constructs, pharmacological compositions, and methods of administration of the nucleic acid constructs that are effective in treating the neuropathic pain.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1? (SDF-1?); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1?. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1? or a polynucleotide codes a protein thereof.

Abstract: The present invention relates to a DNA construct encoding one or more human IGF-1 isoforms that can be used for treatment of neuropathy. Further provided herein are a pharmaceutical composition including the DNA construct as an active ingredient and a method of administering the DNA construct for treatment of neuropathy. The present invention provides a safe and effective way of treating neuropathic patients.

Abstract: The present invention relates to a method of treating neuropathy by administering DNA constructs, encoding a human IGF-1 isoform and a human HGF isoform. Further provided herein are various DNA constructs and pharmaceutical compositions including the DNA constructs that can be used for the combination therapy. The present invention provides a safe and effective way of treating neuropathic patients.

Abstract: The present invention relates to methods of treating chemotherapy-induced peripheral neuropathy. In particular, the methods provide a new way of reducing neuropathic pain associated with chemotherapy-induced peripheral neuropathy by administering a nucleic acid construct encoding human HGF proteins. This application further provides nucleic acid constructs, pharmacological compositions, and methods of administration of the nucleic acid constructs that are effective in treating the neuropathic pain.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1? (SDF-1?); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1?. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1? or a polynucleotide codes a protein thereof.